Exscientia is the first company to actually automate drug design, surpassing conventional human endeavor. With the help of artificial intelligence (AI) and big data resources, Exscientia is accelerating the speed of drug development. Exscientia’s AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. By harnessing the power of big data, the company has better information at hand than any researcher could acquire individually. Knowledge-powered systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated,the results are integrated and the next design cycle initiated. Drug discovery has never been this fast! Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.